Skin

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Retrieved on: 
Thursday, April 11, 2024
Janus, Autoantibody, Glomerulonephritis, Brain, Blood, Inflammation, EDT, Skin, Survival, Pathology, Lupus, Joint, CD19, Autoimmune disease, Patient, Acquisition, DSM-IV codes, Immune system, Therapy, Vaccine

SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.

Key Points: 
  • In support of the acquisition, Eliem has entered into a securities purchase agreement for a $120 million private placement of common stock with a syndicate of new and existing institutional life science investors including RA Capital Management, Deep Track Capital, Boxer Capital, Janus Henderson Investors, Pontifax and Samsara Biocapital.
  • The private placement is expected to close concurrently with the closing of the acquisition.
  • Immediately following the closing of the acquisition and the private placement, the total cash and cash equivalents of the combined company are expected to be approximately $210 million.
  • The acquisition and private placement are expected to close in the middle of 2024, subject to approval by Eliem’s stockholders and other customary closing conditions.

EveLab Insight Furthers Its Reach into the European Market at Cosmoprof Bologna

Retrieved on: 
Wednesday, April 10, 2024
Insight, Skin, Research, Artificial intelligence, Science, Movement, Database, Growth, Deep learning

SINGAPORE, April 10, 2024 (GLOBE NEWSWIRE) -- Hundreds of visitors personally experienced the future of skincare analysis at the EveLab Insight booth at Cosmoprof Bologna. This showcase of technology and innovation marked the launch of an accelerated growth strategy into Europe's fast-growing boutique skincare segment.

Key Points: 
  • SINGAPORE, April 10, 2024 (GLOBE NEWSWIRE) -- Hundreds of visitors personally experienced the future of skincare analysis at the EveLab Insight booth at Cosmoprof Bologna.
  • "At EveLab Insight, we're committed to revolutionizing skincare through science and personalization," emphasized Michel Lin, Senior Business Development Manager of Europe.
  • With Cosmoprof Bologna serving as a pivotal platform for EveLab Insight's expansion into the European market, the company is poised to continue its journey of innovation and impact on a global scale.
  • To learn more about EveLab Insight and its pioneering skin analysis technology, visit www.evelabinsight.com and join the movement towards personalized skincare excellence.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
Wednesday, April 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

truInsights into Pet Allergies: Trupanion Decodes Trends and Provides Tips for Pet Parents

Retrieved on: 
Thursday, April 25, 2024
Software, Other Health, Professional Services, Data Management, Consumer, Technology, Health Insurance, Data Analytics, Veterinary, Insurance, Practice Management, Health, Pets, CVA, Pet, Safety, Skin, Allergy, Parent, Cat, Human, Flea, Parasitism, Database, Dog, Bachelor of Veterinary Science, Trupanion

For pet parents concerned about allergies affecting their furry companions, Trupanion consulted with veterinarian and Trupanion General Manager, Dr. Stephen Rose, BVSc (Hons1) M Infotech CVA ACVCHM, for his insights.

Key Points: 
  • For pet parents concerned about allergies affecting their furry companions, Trupanion consulted with veterinarian and Trupanion General Manager, Dr. Stephen Rose, BVSc (Hons1) M Infotech CVA ACVCHM, for his insights.
  • “Allergies, much like in humans, can have broad health implications, affecting skin, ears, eyes, feet, and even internal organs,” said Dr. Rose.
  • “Allergies are less seldom triggered by a singular factor but rather accumulate from multiple triggers, ultimately prompting the need for treatment.
  • For Trupanion-covered pets in North America, the highest number of allergy related claims over the past 3 years occurred in these states or provinces:

carafem Expands Compassionate, Convenient 24/7 Telehealth Abortion Care to New York

Retrieved on: 
Wednesday, April 24, 2024
Convenience Store, Telemedicine, Virtual Medicine, Vacation, Health Technology, Women, Science, Seniors, Retail, Men, Health, Family, Consumer, Online Retail, Discount, Variety, Teens, Baby, Maternity, Healthcare Reform, Public Policy, Other Policy Issues, LGBTQ+, Travel, Practice Management, Elections, Campaigns, Other Health, General Health, Government, Pharmaceutical, Other Science, FDA, City, Mifepristone, Misoprostol, Language, Privacy, Gender identity, Physician, New Yorker, Pregnancy, Skin, Birth control

carafem , the nation’s most trusted provider of telehealth abortion care, announced today the expansion of its private, personalized abortion services across the state of New York.

Key Points: 
  • carafem , the nation’s most trusted provider of telehealth abortion care, announced today the expansion of its private, personalized abortion services across the state of New York.
  • carafem will provide New Yorkers with a reliable and convenient telehealth option for abortion care, available any time of day or night starting online from their website at carafem.org.
  • “carafem is proud to provide confidential, affordable, and reliable abortion care with 24/7 access in the city that never sleeps.
  • With telehealth abortion care, we’re able to break down more barriers to access.

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Goldman Sachs, American Academy, Hart–Scott–Rodino Antitrust Improvements Act, B cell, LLP, Safety, Skin, Vital signs, Centerview Partners, Research, ECG, Covington & Burling, MRGPRX2, MRGPRX4, Autoimmunity, Therapy, Science, Escient, Incidence, Patient, Acquisition, Multimedia, Atopic dermatitis, CSU

This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Key Points: 
  • This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “These drug candidates are the result of the highly innovative research performed by Escient’s employees and scientific collaborators,” said Joshua A. Grass, President and Chief Executive Officer, Escient.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction and Fenwick & West LLP acted as legal counsel for Escient.
  • The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415.

Ground-Breaking, Drug-Free, and Clinically Tested BackVive Patch Offers Long-Lasting Relief to Chronic Back Pain Sufferers

Retrieved on: 
Tuesday, April 23, 2024
Health Technology, Health, Medical Devices, Chronic pain, Pain, Brain, Narcotic, Skin, Acupuncture, Tissue, OTC, MD, Trial of the century, Depression, Suicide, Patient, Physician, Back pain, Multimedia, Gel, Disability

Chronic back pain frustrates tens of millions of Americans who have struggled to find relief for their unrelenting pain.

Key Points: 
  • Chronic back pain frustrates tens of millions of Americans who have struggled to find relief for their unrelenting pain.
  • View the full release here: https://www.businesswire.com/news/home/20240423679798/en/
    New drug-free BackVive patch offers long-lasting relief to the tens of millions of Americans suffering from chronic back pain.
  • The BackVive patch is convenient, clinically tested, virtually painless, and provides long-lasting relief.
  • Additionally, the pain relief lasted for a week in most of the cases with only a single application of BackVive.

Medical Adhesives & Sealants World Market Report 2024: Remineralizing Agents Being Used to Restore Resin-Based Dental Materials - ResearchAndMarkets.com

Retrieved on: 
Monday, April 22, 2024
Medical Supplies, Health, Internal, Acrylic, Catheter, Polyurethane, Instrument, Metal, Dental, Fibrin, Cosmetics, Skin, Dentistry, USB On-The-Go, Medical device, Polymer, Suture, Plastic surgery, Adhesive, Surgical instrument, Equipment

The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.
  • There are several applications for adhesives and sealants the medical sector, including in the areas of dentistry & cosmetics, internal & external surgery and medical devices & equipment.
  • Among these, acrylic, silicone, polyurethane, polyethylene glycol and cyanoacrylate are most widely used materials to make synthetic/semi-synthetic adhesives & sealants.
  • This world market compendium analyzes the market for Medical Adhesives & Sealants at a high level by resin type/sub-type, application, end-use sector and geographic region.

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Retrieved on: 
Monday, April 22, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Staphylococcus epidermidis, Protein, Skin, Abstract, LEKTI, Patient, Dermatology, Netherton syndrome, Vaccine

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.
  • ATR-12 has been engineered to deliver missing LEKTI protein when applied topically to Netherton syndrome patients.
  • The data in the abstracts released online today show that topical application of ATR-12 in preclinical models reduced produced reduced IL-36γ by 93% compared to skin extracts induced to overexpress IL-36γ.
  • Additionally, topical application of ATR-12 significantly reduced protease activity in skin samples compared to a Netherton syndrome model skin (p

P&G Announces Fiscal Year 2024 Third Quarter Results

Retrieved on: 
Friday, April 19, 2024
Other Retail, Supermarket, Specialty, Food, Beverage, Consumer, Discount, Variety, Other Consumer, Retail, SK-II, P&G, Child, Cough, Home care, Incidence, Health care, EPS, Skin, Groom, GAAP, Growth

Operating margin for the quarter increased 90 basis points versus the prior year, 220 basis points on a currency-neutral basis.

Key Points: 
  • Operating margin for the quarter increased 90 basis points versus the prior year, 220 basis points on a currency-neutral basis.
  • The Company now expects a benefit of approximately $900 million after tax from favorable commodity costs for fiscal year 2024.
  • P&G now expects a core effective tax rate of 20% to 21% in fiscal 2024.
  • Capital spending is estimated to be approximately 4% of fiscal 2024 net sales.